Tissue penetration of antimicrobials: Difference between revisions
From IDWiki
(ββ) |
(ββ) |
||
Line 11: | Line 11: | ||
! colspan="7" |Antibiotics: Ξ²-Lactams |
! colspan="7" |Antibiotics: Ξ²-Lactams |
||
|- |
|- |
||
| rowspan="3" |Penicillins |
| rowspan="3" |[[Penicillins]] |
||
|Ξ²-lactamase inhibitors |
|Ξ²-lactamase inhibitors |
||
| |
| |
||
Line 33: | Line 33: | ||
| |
| |
||
|- |
|- |
||
| rowspan="5" |Cephalosporins |
| rowspan="5" |[[Cephalosporins]] |
||
|first-generation cephalosporins |
|first-generation cephalosporins |
||
| |
| |
||
Line 69: | Line 69: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
| rowspan="2" |Cephamycins |
| rowspan="2" |[[Cephamycins]] |
||
|[[cephamycins]] |
|[[cephamycins]] |
||
| |
| |
||
Line 84: | Line 84: | ||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
|- |
|- |
||
|Carbapenems |
|[[Carbapenems]] |
||
|[[imipenem]] |
|[[imipenem]] |
||
| |
| |
||
Line 94: | Line 94: | ||
! colspan="7" |Antibiotics: Non-Ξ²-Lactams |
! colspan="7" |Antibiotics: Non-Ξ²-Lactams |
||
|- |
|- |
||
|Aminoglycosides |
|[[Aminoglycosides]] |
||
| |
| |
||
| |
| |
||
Line 102: | Line 102: | ||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
|- |
|- |
||
|Chloramphenicol |
|[[Chloramphenicol]] |
||
|[[chloramphenicol]] |
|[[chloramphenicol]] |
||
| |
| |
||
Line 110: | Line 110: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
|Fluoroquinolones |
|[[Fluoroquinolones]] |
||
| |
| |
||
| |
| |
||
Line 118: | Line 118: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
|Fosfomycin |
|[[Fosfomycin]] |
||
|[[fosfomycin]] |
|[[fosfomycin]] |
||
| |
| |
||
Line 126: | Line 126: | ||
| |
| |
||
|- |
|- |
||
|Lincosamides |
|[[Lincosamides]] |
||
|[[clindamycin]] |
|[[clindamycin]] |
||
| |
| |
||
Line 134: | Line 134: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
|Macrolides |
|[[Macrolides]] |
||
|[[macrolides]] |
|[[macrolides]] |
||
| |
| |
||
Line 142: | Line 142: | ||
| |
| |
||
|- |
|- |
||
|Nitrofurans |
|[[Nitrofurans]] |
||
|[[nitrofurantoin]] |
|[[nitrofurantoin]] |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
Line 150: | Line 150: | ||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
|- |
|- |
||
|Nitroimidazoles |
|[[Nitroimidazoles]] |
||
|[[metronidazole]] |
|[[metronidazole]] |
||
| |
| |
||
Line 158: | Line 158: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
|Rifamycins |
|[[Rifamycins]] |
||
|[[rifampin]] |
|[[rifampin]] |
||
| |
| |
||
Line 166: | Line 166: | ||
| |
| |
||
|- |
|- |
||
|Sulfonamides |
|[[Sulfonamides]] |
||
|[[trimethoprim-sulfamethoxazole]] |
|[[trimethoprim-sulfamethoxazole]] |
||
| |
| |
||
Line 174: | Line 174: | ||
| |
| |
||
|- |
|- |
||
| rowspan="2" |Tetracyclines |
| rowspan="2" |[[Tetracyclines]] |
||
|[[tetracyclines]] |
|[[tetracyclines]] |
||
| |
| |
||
Line 191: | Line 191: | ||
! colspan="7" |Antifungals |
! colspan="7" |Antifungals |
||
|- |
|- |
||
|Azoles |
|[[Azoles]] |
||
|[[fluconazole]] |
|[[fluconazole]] |
||
| |
| |
||
Line 198: | Line 198: | ||
| |
| |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|||
|[[Echinocandins]] |
|||
| |
|||
| + |
|||
| |
|||
|β |
|||
| |
|||
| |
|||
|- |
|- |
||
!Class |
!Class |
Revision as of 18:46, 16 September 2020
Summary
Class | Antimicrobial | Blood | CNS | Urine | Prostate | Necrotic |
---|---|---|---|---|---|---|
Antibiotics: Ξ²-Lactams | ||||||
Penicillins | Ξ²-lactamase inhibitors | β | ||||
ampicillin | + | β | ||||
piperacillin-tazobactam | +β | |||||
Cephalosporins | first-generation cephalosporins | β | β | |||
second-generation cephalosporins | β | |||||
third-generation cephalosporins | +β | |||||
cefepime | + | |||||
ceftazidime | + | + | ||||
Cephamycins | cephamycins | β | ||||
cefoxitin | β | |||||
Carbapenems | imipenem | + | ||||
Antibiotics: Non-Ξ²-Lactams | ||||||
Aminoglycosides | β | |||||
Chloramphenicol | chloramphenicol | + | ||||
Fluoroquinolones | β? | + | + | |||
Fosfomycin | fosfomycin | + | ||||
Lincosamides | clindamycin | β | + | |||
Macrolides | macrolides | β | + | |||
Nitrofurans | nitrofurantoin | β | β | + | β | β |
Nitroimidazoles | metronidazole | + | ||||
Rifamycins | rifampin | + | ||||
Sulfonamides | trimethoprim-sulfamethoxazole | + | ||||
Tetracyclines | tetracyclines | β | + | |||
doxycycline | + | + | ||||
Antifungals | ||||||
Azoles | fluconazole | + | ||||
Echinocandins | + | β | ||||
Class | Antimicrobial | Blood | CNS | Urine | Prostate | Necrotic |
- β if inflammation present
Prostate
- Poorly penetrated by most antibiotics
- Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
- Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
- TMP-SMX often used, though conflicting data about its penetration into the prostate
- Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
- Third-generation cephalosporins and carbapenems can be used
- Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful
References
- ^ Tomasz Jodlowski, Charles R Ashby, Sarath G Nath. Doxycycline for ESBL-E Cystitis. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1898.
- a b c d e f g h i Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.
- ^ nau2010pe
- ^ Cornelia B. Landersdorfer, JΓΌrgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz SΓΆrgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
- a b c d e f g h i j k l m n o p q r L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
- a b Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
- ^ Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
- ^ Luis F. LΓ³pez-CortΓ©s, R. Ruiz-Valderas, M. J. Lucero-MuΓ±oz, E. Cordero, M. T. Pastor-Ramos, J. Marquez. Intravitreal, Retinal, and Central Nervous System Foscarnet Concentrations after Rapid Intravenous Administration to Rabbits. Antimicrobial Agents and Chemotherapy. 2000;44(3):756-759. doi:10.1128/aac.44.3.756-759.2000.